Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has GlaxoSmithKline plc (GSK - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
GlaxoSmithKline plc is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GSK is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GSK's full-year earnings has moved 1.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, GSK has moved about 15.28% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.45%. This means that GlaxoSmithKline plc is outperforming the sector as a whole this year.
Looking more specifically, GSK belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 9.85% so far this year, meaning that GSK is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track GSK. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has GlaxoSmithKline plc (GSK - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
GlaxoSmithKline plc is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GSK is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for GSK's full-year earnings has moved 1.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, GSK has moved about 15.28% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.45%. This means that GlaxoSmithKline plc is outperforming the sector as a whole this year.
Looking more specifically, GSK belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 9.85% so far this year, meaning that GSK is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track GSK. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GSK - FREE